An outstanding candidate for a human anti-cancer treatment
EBC-46 is a novel natural product small molecule with anticancer activity being developed as a local treatment for solid tumours in humans and companion animals (dogs, cats and horses). EBC-46 was discovered by applying the EcoLogic™ approach to drug discovery from the tropical rainforests of Far North Queensland. EcoLogic™ was developed by QBiotics’ parent entity EcoBiotics.
QBiotics plans to develop EBC-46 as a human pharmaceutical to Clinical Phase II and then seek a development partner for final development and marketing of the drug. QBiotics has already demonstrated very compelling proof-of-concept of the drug's efficacy and safety by successfully treating advanced, spontaneous tumours in companion animals that were considered untreatable with current standards of care. As the principles behind the development of cancer in animals and humans are analogous, it is likely that EBC-46 will have similar effects in humans as in animals.
Potential indications for the drug include:
Testing EBC-46 in vitro against various cancer cell lines, in mouse models of cancer, and in companion animals with cancer, has demonstrated that the drug has broad activity against many different tumour types including:
- Skin cancers, such as squamous cell carcinomas (SCC), basal cell carcinomas (BCC) and melanomas;
- Head & neck cancers;
- Breast cancers;
- Prostate cancers; and
- Colorectal cancers.
Clinical trials in humans
QBiotics Ltd is not able to provide treatment with EBC-46 at this time. Recruitment for the two Phase I safety studies in Australia and New Zealand is now closed and QBiotics does not currently have any other open trials. QBiotics will proceed to analyse and report on the Phase I studies, and then make a determination on how best to continue with clinical development for eventual approval of EBC-46. Details of any future clinical trials will be posted on the company’s website and international clinical trial registries, such as ClinicalTrials.gov.
Please note that:
- QBiotics is not involved in assessing patients or recommending eligibility - this is something only the independent treating clinicians can determine.
- QBiotics staff are unable to discuss any aspects of these trials with potential patients and unfortunately we cannot respond to emails or phone requests for information about these clinical trials from the general public.